James Parsons, MD
Geriatric Medicine · Raleigh, NCNPI 1255372371
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $7,328 of the $9,431 with a category attached, or 77.7%. 17 manufacturers reported payments, led by Novo Nordisk at 49.7% of the total. Reporting peaked in 2021 at $4,062 and has fallen 89.5% since, to $427 in 2025. Among geriatric medicine clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 311 payments — averaging $30.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$5K
- Esperion Therapeutics, Inc.$822
- Lilly USA, LLC$712
- AstraZeneca$554
- Astellas Pharma US Inc$463
- AbbVie$449
- plus $2K from 11 others
What the payments were for
- Consulting fees$1,62017%
- Food & beverage$7,32878%
- Education$4835%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 141 | $4,691 |
| Esperion Therapeutics, Inc. | 19 | $822 |
| Lilly USA, LLC | 39 | $712 |
| AstraZeneca | 10 | $554 |
| Astellas Pharma US Inc | 5 | $463 |
| AbbVie(2 entities) | 27 | $449 |
| Boehringer Ingelheim | 9 | $419 |
| Amgen(2 entities) | 8 | $411 |
| Pfizer | 19 | $303 |
| Sanofi-aventis U.S. LLC | 14 | $215 |
| Eisai Inc. | 2 | $136 |
| Kowa Pharmaceuticals America, Inc. | 9 | $120 |
| Exact Sciences | 5 | $83 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
| Almatica Pharma LLC | 1 | $15 |
| Mylan Specialty L.p. | 1 | $13 |
| Sumitomo Pharma America, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,431 in reported general payments places this provider in the 95th percentile of 138 geriatric medicine providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 121 | $187,511 |
| EliquisApixaban | 62 | $65,496 |
| MounjaroTirzepatide | 48 | $64,293 |
| XareltoRivaroxaban | 36 | $33,251 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 19 | $24,919 |
| FarxigaDapagliflozin Propanediol | 13 | $10,266 |
| Aripiprazole | 31 | $6,627 |
| MyrbetriqMirabegron | 13 | $6,367 |
| NexlizetBempedoic Acid/Ezetimibe | 13 | $6,069 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 11 | $5,113 |
| Rosuvastatin Calcium | 436 | $5,099 |
| Nebivolol Hcl | 69 | $4,592 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 12 | $3,235 |
| Atorvastatin Calcium | 249 | $2,771 |
| Losartan Potassium | 221 | $2,463 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $4,691 | $187,511121 claims |
| PfizerEliquis, Paxlovid | $303 | $66,925100 claims |
| Lilly USA, LLCMounjaro | $712 | $64,29348 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $215 | $24,91919 claims |
| AstraZenecaFarxiga | $554 | $10,26613 claims |
| Astellas Pharma US IncMyrbetriq | $463 | $6,36713 claims |
| Esperion Therapeutics, Inc.Nexlizet | $822 | $6,06913 claims |
| Boehringer IngelheimStiolto Respimat | $419 | $5,11311 claims |
| AbbVieSynthroid | $449 | $1,99831 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 138 geriatric medicine providers in North Carolina.
Other geriatric medicine in Raleigh
- Amish PatelRaleigh$1K
- Iftequar AhmedRaleigh$398
- Saifullah AfridiRaleigh$124
- Robert StewartDurham$103K
- Mary Busby WhiteheadChapel Hill$19K
- Josette MariaDunn$10K
- Golnosh SharafsalehMorganton$10K
- John BatsisChapel Hill$8K
- Kenneth LylesDurham$5K
- Tiffany ReedGreensboro$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.